Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 11, 2023

BUY
$62.68 - $95.05 $216,183 - $327,827
3,449 Added 22.07%
19,077 $1.79 Million
Q1 2023

May 15, 2023

BUY
$47.19 - $70.77 $242,226 - $363,262
5,133 Added 48.91%
15,628 $1.06 Million
Q4 2022

Feb 14, 2023

BUY
$30.35 - $53.15 $318,523 - $557,809
10,495 New
10,495 $519,000
Q2 2022

Aug 15, 2022

SELL
$35.61 - $76.23 $36,607 - $78,364
-1,028 Reduced 6.67%
14,384 $565,000
Q1 2022

May 16, 2022

BUY
$57.56 - $82.54 $3,050 - $4,374
53 Added 0.35%
15,412 $1.08 Million
Q4 2021

Feb 14, 2022

SELL
$72.5 - $100.68 $290,725 - $403,726
-4,010 Reduced 20.7%
15,359 $1.2 Million
Q3 2021

Nov 12, 2021

BUY
$90.24 - $124.05 $454,177 - $624,343
5,033 Added 35.11%
19,369 $1.85 Million
Q2 2021

Aug 13, 2021

BUY
$93.66 - $139.27 $133,371 - $198,320
1,424 Added 11.03%
14,336 $1.78 Million
Q1 2021

May 14, 2021

BUY
$116.57 - $155.01 $431,891 - $574,312
3,705 Added 40.24%
12,912 $1.7 Million
Q4 2020

Feb 08, 2021

BUY
$99.61 - $142.12 $458,106 - $653,609
4,599 Added 99.8%
9,207 $1.22 Million
Q3 2020

Nov 12, 2020

BUY
$72.92 - $102.01 $42,074 - $58,859
577 Added 14.31%
4,608 $470,000
Q2 2020

Jul 17, 2020

BUY
$55.75 - $92.75 $224,728 - $373,875
4,031 New
4,031 $351,000
Q3 2019

Nov 13, 2019

SELL
$90.37 - $122.49 $337,170 - $457,010
-3,731 Closed
0 $0
Q2 2019

Aug 12, 2019

SELL
$89.51 - $118.04 $156,284 - $206,097
-1,746 Reduced 31.88%
3,731 $440,000
Q1 2019

May 08, 2019

SELL
$61.98 - $96.5 $97,246 - $151,408
-1,569 Reduced 22.27%
5,477 $474,000
Q4 2018

Feb 14, 2019

SELL
$56.04 - $82.66 $9,414 - $13,886
-168 Reduced 2.33%
7,046 $445,000
Q3 2018

Nov 14, 2018

BUY
$48.29 - $80.6 $87,791 - $146,530
1,818 Added 33.69%
7,214 $569,000
Q2 2018

Aug 14, 2018

BUY
$37.84 - $69.96 $15,590 - $28,823
412 Added 8.27%
5,396 $323,000
Q1 2018

May 14, 2018

BUY
$39.82 - $57.53 $198,462 - $286,729
4,984 New
4,984 $224,000

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $10.2B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Vident Investment Advisory, LLC Portfolio

Follow Vident Investment Advisory, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vident Investment Advisory, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Vident Investment Advisory, LLC with notifications on news.